A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2019
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors MedImmune
- 03 Jan 2019 Planned End Date changed from 1 Feb 2019 to 8 Feb 2019.
- 03 Jan 2019 Planned primary completion date changed from 1 Feb 2019 to 8 Feb 2019.
- 03 Jan 2019 Status changed from recruiting to active, no longer recruiting.